ECSP088992A - Inhibidores de akt (proteina cinasa b) - Google Patents

Inhibidores de akt (proteina cinasa b)

Info

Publication number
ECSP088992A
ECSP088992A EC2008008992A ECSP088992A ECSP088992A EC SP088992 A ECSP088992 A EC SP088992A EC 2008008992 A EC2008008992 A EC 2008008992A EC SP088992 A ECSP088992 A EC SP088992A EC SP088992 A ECSP088992 A EC SP088992A
Authority
EC
Ecuador
Prior art keywords
cinase
protein
akt inhibitors
compounds
salt
Prior art date
Application number
EC2008008992A
Other languages
English (en)
Inventor
Michael Ray Myers
Christopher Randall Schmid
Renhua Li
Sajan Joseph
Aktham Aburub
Jenny Pinggi Dai
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP088992A publication Critical patent/ECSP088992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol o una sal del mismo farmacéuticamente aceptable o un hidrato del compuesto o la sal del mismo, como inhibidores de AKt, que son agentes antineoplásicos y/o antivirales, así como también a composiciones que comprende estos compuestos y a métodos para usar estos compuestos
EC2008008992A 2006-06-20 2008-12-18 Inhibidores de akt (proteina cinasa b) ECSP088992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80526006P 2006-06-20 2006-06-20
US88576507P 2007-01-19 2007-01-19

Publications (1)

Publication Number Publication Date
ECSP088992A true ECSP088992A (es) 2009-01-30

Family

ID=38834248

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008992A ECSP088992A (es) 2006-06-20 2008-12-18 Inhibidores de akt (proteina cinasa b)

Country Status (28)

Country Link
US (1) US7998977B2 (es)
EP (1) EP2035385B1 (es)
JP (1) JP2009541335A (es)
KR (1) KR101067551B1 (es)
AR (1) AR061240A1 (es)
AT (1) ATE455102T1 (es)
AU (1) AU2007261120A1 (es)
BR (1) BRPI0713136A2 (es)
CA (1) CA2652612A1 (es)
CL (1) CL2007001752A1 (es)
DE (1) DE602007004333D1 (es)
DK (1) DK2035385T3 (es)
DO (1) DOP2008000053A (es)
EA (1) EA015712B1 (es)
EC (1) ECSP088992A (es)
ES (1) ES2336630T3 (es)
HR (1) HRP20100147T1 (es)
IL (1) IL195005A0 (es)
MA (1) MA30757B1 (es)
MX (1) MX2008015904A (es)
NO (1) NO20090289L (es)
PE (1) PE20080338A1 (es)
PL (1) PL2035385T3 (es)
PT (1) PT2035385E (es)
SI (1) SI2035385T1 (es)
TN (1) TNSN08529A1 (es)
TW (1) TW200812970A (es)
WO (1) WO2007149730A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EA028343B1 (ru) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Лечение дегенеративного заболевания сустава
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
RU2736513C2 (ru) 2014-08-18 2020-11-17 Ампио Фармасьютикалз, Инк. Лечение патологических состояний суставов
US10123997B2 (en) * 2015-06-15 2018-11-13 Yong Liao Target for treating hepatitis B virus
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2022017448A1 (zh) * 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
US20230321108A1 (en) * 2020-07-22 2023-10-12 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Unit dosage composition of akt inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
WO2004094386A1 (en) * 2003-03-28 2004-11-04 Eli Lilly And Company Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
GB0317315D0 (en) 2003-07-24 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
US7449477B2 (en) * 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)

Also Published As

Publication number Publication date
WO2007149730A2 (en) 2007-12-27
TNSN08529A1 (en) 2010-04-14
CA2652612A1 (en) 2007-12-27
EP2035385B1 (en) 2010-01-13
AU2007261120A1 (en) 2007-12-27
TW200812970A (en) 2008-03-16
HRP20100147T1 (hr) 2010-04-30
SI2035385T1 (sl) 2010-05-31
DOP2008000053A (es) 2009-01-15
MX2008015904A (es) 2009-01-12
EA015712B1 (ru) 2011-10-31
BRPI0713136A2 (pt) 2012-04-17
AR061240A1 (es) 2008-08-13
IL195005A0 (en) 2009-08-03
ATE455102T1 (de) 2010-01-15
JP2009541335A (ja) 2009-11-26
ES2336630T3 (es) 2010-04-14
WO2007149730A3 (en) 2008-04-24
US20090221633A1 (en) 2009-09-03
PE20080338A1 (es) 2008-04-25
PT2035385E (pt) 2010-03-01
MA30757B1 (fr) 2009-10-01
DK2035385T3 (da) 2010-03-22
CL2007001752A1 (es) 2008-01-18
US7998977B2 (en) 2011-08-16
PL2035385T3 (pl) 2010-06-30
DE602007004333D1 (de) 2010-03-04
KR20090015978A (ko) 2009-02-12
KR101067551B1 (ko) 2011-09-27
EP2035385A2 (en) 2009-03-18
EA200970041A1 (ru) 2009-06-30
NO20090289L (no) 2009-01-19

Similar Documents

Publication Publication Date Title
ECSP088992A (es) Inhibidores de akt (proteina cinasa b)
EA200970856A1 (ru) Ингибиторы пути хеджхога
GT201100181A (es) "inhibidores de proteina cinasa"
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
UA94129C2 (ru) Соединения для ингибирования митоза
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
CR20110339A (es) Compuestos útiles para inhibir chk1
CY1118012T1 (el) Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες
UY32730A (es) Inhibidores de cyp17
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
ECSP055867A (es) Derivados de pirrolopirimidina
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
CO6440548A2 (es) 1-/arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6.
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
GT200600117A (es) Nuevos compuestos farmaceuticos
CR10199A (es) Derivados de benzimidazol
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
NI201100035A (es) Agentes antifúngicos.
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
PA8593701A1 (es) [4-(3-aminometilfenil)piperidin-1-il]-[5-(2-fluorofenil-etinil)furan-2-il]-metanoma como inhibidor de triptasa de mastocitos
GT200600132A (es) Una oxindoloxazolidinona como agente antibacteriano
CY1117072T1 (el) Ενωσεις αναστολης της μιτωτικης διαδικασιας